Nicholas Scott Heaton

Associate Professor of Molecular Genetics and Microbiology
Appointments and Affiliations
- Associate Professor of Molecular Genetics and Microbiology
- Member of the Duke Cancer Institute
- Member of the Duke Human Vaccine Institute
Contact Information
- Email Address: nicholas.heaton@duke.edu
Education
- Ph.D. The University of Chicago, 2012
Courses Taught
- MGM 593: Research Independent Study
- MGM 701: Foundations of Molecular Genetics and Microbiology
In the News
- School of Medicine Researchers Honored for Study of the Pathogenesis of Infectious Disease (May 25, 2021 | School of Medicine)
- Estrogen Receptors in Mom’s Placenta Critical During Viral Infection (Jan 21, 2021)
- Sniffing Out COVID-Related Loss of Smell (Jan 11, 2021 | Duke Health News)
- Scent-Sensing Cells Have a Better Way to Fight Flu (Sep 1, 2020)
- Lung Cell Patches Its Own DNA on the Fly to Survive Influenza (Jul 29, 2019)
- Microbiology Society Recognizes Two Duke Researchers (Sep 6, 2018)
- New Vaccine Production Could Improve Flu Shot Accuracy (Jul 24, 2017)
Representative Publications
- Trimarco, JD; Heaton, NS, From high-throughput to therapeutic: host-directed interventions against influenza viruses., Curr Opin Virol, vol 53 (2022) [10.1016/j.coviro.2021.12.014] [abs].
- Harding, AT; Heaton, NS, The Impact of Estrogens and Their Receptors on Immunity and Inflammation during Infection., Cancers, vol 14 no. 4 (2022) [10.3390/cancers14040909] [abs].
- Froggatt, HM; Heaton, NS, Nonrespiratory sites of influenza-associated disease: mechanisms and experimental systems for continued study., Febs J (2022) [10.1111/febs.16363] [abs].
- Froggatt, HM; Burke, KN; Chaparian, RR; Miranda, HA; Zhu, X; Chambers, BS; Heaton, NS, Influenza A virus segments five and six can harbor artificial introns allowing expanded coding capacity., Plos Pathog, vol 17 no. 9 (2021) [10.1371/journal.ppat.1009951] [abs].
- Drayman, N; DeMarco, JK; Jones, KA; Azizi, S-A; Froggatt, HM; Tan, K; Maltseva, NI; Chen, S; Nicolaescu, V; Dvorkin, S; Furlong, K; Kathayat, RS; Firpo, MR; Mastrodomenico, V; Bruce, EA; Schmidt, MM; Jedrzejczak, R; Muñoz-Alía, MÁ; Schuster, B; Nair, V; Han, K-Y; O'Brien, A; Tomatsidou, A; Meyer, B; Vignuzzi, M; Missiakas, D; Botten, JW; Brooke, CB; Lee, H; Baker, SC; Mounce, BC; Heaton, NS; Severson, WE; Palmer, KE; Dickinson, BC; Joachimiak, A; Randall, G; Tay, S, Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2., Science, vol 373 no. 6557 (2021), pp. 931-936 [10.1126/science.abg5827] [abs].